Analysts Are Bullish on These Healthcare Stocks: Vericel Corp (VCEL), Erytech Pharma SA (ERYP)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vericel Corp (VCEL) and Erytech Pharma SA (ERYP) with bullish sentiments.

Vericel Corp (VCEL)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vericel Corp today and set a price target of $32. The company’s shares opened today at $17.22.

DeGeeter said:

“On 5/7/19, VCEL reported 1Q19 financial results and licensed North American rights to NexoBrid from MediWound. Important takeaways include: 1) 2019 revenue guidance raised $2M to $110M-$114M; 2) upside driven by productivity of MACI reps and not incremental new sales rep adds; 3) -13% 1Q19 Epicel growth is focus of some investors; and 4) NexoBrid targets $200M market in North America for burn patients with eschar. On net, we expect NexoBrid to contribute up to $45M of incremental revenue in 2023, which drives our increase in PT from $23 to $32. We continue to view completion review of MACI sales force size this summer as a potential catalyst for communicating an updated outlook for 2H19 and 2020 growth.”

According to TipRanks.com, DeGeeter is a 4-star analyst with an average return of 13.0% and a 49.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vericel Corp with a $22.50 average price target.

See today’s analyst top recommended stocks >>

Erytech Pharma SA (ERYP)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Erytech Pharma SA today. The company’s shares opened today at $7.32, close to its 52-week low of $5.45.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.8% and a 41.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Molecular Templates Inc, and CytomX Therapeutics Inc.

The the analyst consensus on Erytech Pharma SA is currently a Moderate Buy rating.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts